We report the first synthetic peptide vaccine eliciting strong CD8(+) and CD4(+) T lymphocyte responses in humans. The vaccine, representing the C-terminal region of the circumsporozoite protein of Plasmodium falciparum (amino acids 282-383) was well tolerated and strong sporozoite-specific antibodies were elicited. In addition, robust lymphocyte proliferation responses were equally elicited with concomitant in vitro production of IFN-gamma, crucial in the elimination of the parasite. Most importantly, we also observed the development of CD8(+) T lymphocyte responses decisive in the immunity to malaria. The latter finding opens new, possibly safer, avenues for vaccination strategies when a CD8(+) T cell response is needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/1521-4141(200107)31:7<1989::aid-immu1989>3.0.co;2-m | DOI Listing |
Stem Cells
January 2025
Sangamo Therapeutics, 501 Canal Blvd. Richmond, CA.
iPSCs can serve as a renewable source of a consistent edited cell product, overcoming limitations of primary cells. While feeder-free generation of clinical grade iPSC-derived CD8 T cells has been achieved, differentiation of iPSC-derived CD4sp and regulatory T cells requires mouse stromal cells in an artificial thymic organoid. Here we report a serum- and feeder-free differentiation process suitable for large-scale production.
View Article and Find Full Text PDFMikrobiyol Bul
January 2025
Sağlık Bilimleri Üniversitesi, Kayseri Şehir Eğitim ve Araştırma Hastanesi, Parazitoloji Laboratuvarı, Kayseri.
Sıtma, her yıl dünya nüfusunun yarısından fazlası için ciddi bir tehdit oluşturmaya devam etmektedir. Hastalığa neden olan Plasmodium parazitleri, yalnızca insanlarla sınırlı kalmayıp sürüngenlerden kuşlara, memelilerden diğer omurgalılara dek geniş enfeksiyon yelpazesine sahiptir. Plasmodium türleri, çevredeki değişikliklere uyum sağlamalarını sağlayan olağanüstü genetik esnekliğe sahiptir ve bu da onlara sıtma ilaçları gibi tedavi edici maddelere karşı hızla direnç geliştirme ve konakçı özgüllüğünü değiştirme potansiyeli verir.
View Article and Find Full Text PDFBrain Behav Immun Health
February 2025
Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, University of Eastern Piedmont, 28100, Novara, Italy.
Major Depressive Disorder (MDD) is a widespread psychiatric condition impacting social and occupational functioning, making it a leading cause of disability. The diagnosis of MDD remains clinical, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, as biomarkers have not yet been validated for diagnostic purposes or as predictors of treatment response. Traditional treatment strategies often follow a one-size-fits-all approach obtaining suboptimal outcomes for many patients who fail to experience response or recovery.
View Article and Find Full Text PDFIran J Basic Med Sci
January 2025
Department of Medical Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Objectives: Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that have vital roles in activating further immune responses. However, due to their tumor-induced diversity, we decided to examine ILCs, T cells, and the associated cytokines in mouse models of breast cancer.
Materials And Methods: 4T1 and MC4-L2 cells were used to induce triple-negative and hormone-receptor-positive breast cancer, respectively.
Mol Ther Methods Clin Dev
March 2025
Immunologie-Oncologie, Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
CD4CD8 TCRαβ (double-negative [DN]) T cells represent a rare T cell population that promotes immunological tolerance through various cytotoxic mechanisms. In mice, autologous transfer of DN T cells has shown protective effects against autoimmune diabetes and graft-versus-host disease. Here, we characterized human DN T cells from people living with type 1 diabetes (PWT1D) and healthy controls.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!